Moneycontrol
HomeNewsBusinessReal EstateUnsold affordable housing stock declines 21% in two years as supply shrinks
Trending Topics

Unsold affordable housing stock declines 21% in two years as supply shrinks

Unsold affordable houses in the top seven cities declined from 2,34,600 units in the first quarter of 2020 to 1,86,150 by the end of Q1 2022. Unsold ultra-luxury homes declined 5 percent during the period on rising demand

April 19, 2022 / 13:14 IST
Story continues below Advertisement

The inventory of unsold affordable houses has been shrinking over the last two years as the new supply slows down. 

The number of unsold affordable houses in the top seven cities of the country declined by 21 percent–from 2,34,600 units in the first quarter of 2020 to 1,86,150 by the end of Q1 2022, data shared by real estate consultancy Anarock shows.

Story continues below Advertisement

"Affordable housing took the biggest hit from the pandemic, with the first perceivable change being its declining share of new supply,” Anarock Group chairman Anuj Puri said on April 19.

As many as 6,27,780 units lie unsold across the seven cities. Of these, 1,86,150 houses are in the affordable segment, priced at Rs 4o lakh and above, alone. The decline is on account of intentional restrictions on the new budget housing supply.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show